Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Serum Institute of India / Merck & Co.

Serum Institute of India & Merck & Co.

2 shared events · Importance 3 · Last updated Jun 03, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (2)
42
Tech
CEPI Funds Ebola Bundibugyo Vaccine Development
Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.
Merck & Co.: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.
May 22, 2026 · 36 articles
30
Accidents
Unknown Event
Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.
Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.
May 18, 2026 · 505 articles
NEWSDESK
Explore this relationship live

Track how Serum Institute of India and Merck & Co. interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.